| 2023 |
| 12/12 | 595 | 612 | 559 | 587 | -3.77% | 1,687,500 | 69億276万 | -7.85% |
| 12/11 | 686 | 695 | 589 | 610 | -10.82% | 2,963,500 | 71億7323万 | -3.33% |
| 12/08 | 755 | 760 | 669 | 684 | -11.86% | 1,774,400 | 80億4342万 | +9.79% |
| 12/07 | 774 | 794 | 741 | 776 | +1.44% | 880,800 | 91億2529万 | +26.59% |
| 12/06 | 734 | 777 | 730 | 765 | +4.79% | 865,000 | 89億9594万 | +27.71% |
| 12/05 | 701 | 736 | 685 | 730 | +2.38% | 1,038,700 | 85億8436万 | +24.57% |
| 12/04 | 746 | 783 | 711 | 713 | -4.3% | 1,383,200 | 83億8445万 | +24.22% |
| 12/01 | 16:00 第２回日本抗体学会学術大会における講演を行いました |
| 12/01 | 713 | 751 | 691 | 745 | +2.48% | 1,561,600 | 87億6075万 | +32.09% |
| 11/30 | 694 | 741 | 689 | 727 | +3.27% | 1,579,600 | 85億4908万 | +31.23% |
| 11/29 | 695 | 725 | 662 | 704 | -0.56% | 2,189,400 | 82億7861万 | +28.94% |
| 11/28 | 793 | 795 | 695 | 708 | -9% | 3,014,600 | 83億2565万 | +32.34% |
| 11/27 | 732 | 797 | 712 | 778 | +5.28% | 3,557,500 | 91億4881万 | +48.47% |
| 11/24 | 807 | 874 | 716 | 739 | -11.71% | 7,169,000 | 86億9019万 | +44.34% |
| 11/22 | 727 | 879 | 721 | 837 | +14.81% | 7,921,600 | 98億4261万 | +67.07% |
| 11/21 | 758 | 780 | 687 | 729 | -2.67% | 8,027,600 | 85億7260万 | +50% |
| 11/20 | 640 | 749 | 632 | 749 | +15.41% | 9,525,600 | 88億779万 | +57.35% |
| 11/17 | 599 | 649 | 575 | 649 | +18.21% | 10,612,100 | 76億3185万 | +38.97% |
| 11/16 | 510 | 549 | 501 | 549 | +17.06% | 2,146,800 | 64億5591万 | +18.83% |
| 11/15 | 16:00 2024年3月期第2四半期決算説明会資料 |
| 11/15 | 457 | 480 | 442 | 469 | +4.22% | 991,600 | 55億1515万 | +1.08% |
| 11/14 | 436 | 460 | 433 | 450 | +5.14% | 1,508,100 | 52億9173万 | -3.64% |
| 11/13 | 15:05 営業外収益及び特別損失の計上に関するお知らせ |
| 11/13 | 15:05 2024年3月期第2四半期決算短信〔日本基準〕(非連結) |
| 11/13 | 424 | 433 | 419 | 428 | -0.47% | 364,400 | 50億3302万 | -8.94% |
| 11/09 | 460 | 460 | 424 | 430 | -6.11% | 990,100 | 50億5654万 | -9.28% |
| 11/08 | 449 | 461 | 442 | 458 | +2.69% | 791,800 | 53億8580万 | -3.98% |
| 11/07 | 451 | 477 | 442 | 446 | -2.19% | 1,484,600 | 52億4469万 | -6.69% |
| 11/06 | 489 | 512 | 456 | 456 | +4.83% | 3,194,200 | 53億6228万 | -4.8% |
| 11/02 | 430 | 448 | 427 | 435 | +1.87% | 507,800 | 51億1533万 | -9.19% |
| 11/01 | 426 | 432 | 414 | 427 | +2.15% | 622,700 | 50億2126万 | -10.67% |
| 10/31 | 442 | 455 | 413 | 418 | -3.46% | 1,488,400 | 49億1542万 | -12.37% |
| 10/30 | 427 | 443 | 420 | 433 | -0.46% | 736,400 | 50億9182万 | -9.22% |
| 10/27 | 437 | 448 | 406 | 435 | -1.58% | 1,879,200 | 51億1533万 | -8.61% |
| 10/26 | 442 | 455 | 431 | 442 | -5.15% | 1,446,800 | 51億9765万 | -7.34% |
| 10/25 | 491 | 514 | 446 | 466 | -6.8% | 4,150,900 | 54億7988万 | -2.51% |
| 10/24 | 523 | 584 | 462 | 500 | -2.53% | 10,099,800 | 58億7970万 | +4.82% |
| 10/23 | 481 | 513 | 472 | 513 | +18.48% | 2,745,200 | 60億3257万 | +9.15% |
| 10/20 | 15:45 PPMX-T003:真性多血症(PV)第I相試験における被験者組み入れ完了のお知らせ |
| 10/20 | 421 | 465 | 415 | 433 | +2.36% | 1,402,900 | 50億9182万 | -6.07% |
| 10/19 | 473 | 477 | 411 | 423 | -10.95% | 1,320,500 | 49億7422万 | -6.83% |
| 10/18 | 484 | 492 | 465 | 475 | -2.06% | 923,700 | 55億8571万 | +6.03% |
| 10/17 | 459 | 487 | 451 | 485 | +7.54% | 1,382,900 | 57億330万 | +10.48% |
| 10/16 | 514 | 525 | 442 | 451 | -7.96% | 2,376,300 | 53億348万 | +4.64% |
| 10/13 | 523 | 540 | 490 | 490 | -6.31% | 1,280,100 | 57億6210万 | +15.57% |
| 10/12 | 500 | 527 | 485 | 523 | +3.16% | 1,749,900 | 61億5016万 | +26.02% |
| 10/11 | 607 | 694 | 500 | 507 | -15.5% | 7,751,100 | 59億6201万 | +25.19% |
| 10/10 | 570 | 604 | 539 | 600 | +7.14% | 1,921,200 | 70億5564万 | +51.52% |
| 10/06 | 501 | 580 | 480 | 560 | +7.69% | 2,237,000 | 65億8526万 | +46.21% |
| 10/05 | 518 | 538 | 506 | 520 | +0.39% | 1,069,900 | 61億1488万 | +39.78% |
| 10/04 | 497 | 546 | 494 | 518 | +0.19% | 2,142,200 | 60億9136万 | +43.09% |
| 10/03 | 480 | 555 | 479 | 517 | +8.84% | 4,098,400 | 60億7960万 | +46.88% |
| 10/02 | 470 | 481 | 445 | 475 | +1.93% | 1,121,900 | 55億8571万 | +38.48% |
| 09/29 | 16:10 株式会社シェアードリサーチによるアナリストレポート公開のお知らせ |
| 09/29 | 462 | 474 | 438 | 466 | +2.64% | 1,322,800 | 54億7988万 | +39.52% |
| 09/28 | 411 | 468 | 411 | 454 | +10.46% | 2,593,300 | 53億3876万 | +38.84% |
| 09/27 | 16:00 シングルセル・クローニング技術による抗体研究支援サービス提供開始のお知らせ |
| 09/27 | 417 | 435 | 406 | 411 | -2.61% | 781,200 | 48億3311万 | +28.84% |
| 09/26 | 400 | 425 | 386 | 422 | +3.94% | 1,960,900 | 49億6246万 | +34.39% |
| 09/25 | 420 | 438 | 400 | 406 | -1.93% | 2,443,400 | 47億7431万 | +32.25% |
| 09/22 | 15:00 PPMX-T003:アグレッシブNK細胞白血病患者さんへの投与開始のお知らせ |
| 09/22 | 433 | 456 | 399 | 414 | -7.8% | 3,040,100 | 48億6839万 | +37.54% |
| 09/21 | 16:00 第２回日本抗体学会学術大会における講演のお知らせ |
| 09/21 | 452 | 489 | 426 | 449 | -5.67% | 6,496,100 | 52億7997万 | +52.2% |
| 09/20 | 422 | 497 | 387 | 476 | +11.74% | 18,908,800 | 55億9747万 | +65.28% |
| 09/19 | 354 | 426 | 331 | 426 | +23.12% | 7,199,700 | 50億950万 | +52.14% |
| 09/15 | 266 | 346 | 266 | 346 | +30.08% | 1,026,900 | 40億6875万 | +25.82% |
| 09/14 | 264 | 266 | 264 | 266 | 0% | 27,000 | 31億2800万 | -2.21% |
| 09/13 | 264 | 266 | 263 | 266 | 0% | 25,000 | 31億2800万 | -2.56% |
| 09/12 | 270 | 270 | 265 | 266 | -1.12% | 36,900 | 31億2800万 | -2.56% |
| 09/11 | 270 | 273 | 265 | 269 | -1.82% | 28,800 | 31億6327万 | -1.82% |
| 09/08 | 272 | 274 | 270 | 274 | +0.37% | 16,000 | 32億2207万 | 0% |
| 09/07 | 278 | 278 | 272 | 273 | -1.8% | 48,800 | 32億1031万 | -0.36% |
| 09/06 | 277 | 279 | 276 | 278 | +0.36% | 36,900 | 32億6911万 | +1.09% |
| 09/05 | 273 | 279 | 273 | 277 | 0% | 30,700 | 32億5735万 | +0.73% |
| 09/04 | 277 | 278 | 273 | 277 | +0.36% | 26,800 | 32億5735万 | +0.73% |
| 09/01 | 275 | 277 | 273 | 276 | +0.36% | 18,000 | 32億4559万 | +0.36% |
| 08/31 | 274 | 278 | 273 | 275 | +0.36% | 33,000 | 32億3383万 | 0% |
| 08/30 | 274 | 277 | 273 | 274 | -0.72% | 38,900 | 32億2207万 | -0.36% |
| 08/29 | 15:05 （開示事項の経過）富山大学及び富山県とのスーパー中和抗体についての共同研究に関する覚書締結のお知らせ |
| 08/29 | 271 | 277 | 271 | 276 | +1.47% | 25,600 | 32億4559万 | +0.36% |
| 08/28 | 272 | 272 | 261 | 272 | -0.37% | 30,000 | 31億9855万 | -1.45% |
| 08/25 | 268 | 275 | 268 | 273 | 0% | 26,400 | 32億1031万 | -1.09% |
| 08/24 | 274 | 275 | 270 | 273 | +0.74% | 14,400 | 32億1031万 | -1.09% |
| 08/23 | 266 | 273 | 266 | 271 | +1.88% | 14,800 | 31億8679万 | -2.17% |
| 08/22 | 262 | 269 | 262 | 266 | +0.76% | 32,000 | 31億2800万 | -3.97% |
| 08/21 | 255 | 268 | 255 | 264 | +2.33% | 52,600 | 31億448万 | -5.04% |
| 08/18 | 259 | 261 | 255 | 258 | -1.53% | 87,600 | 30億3392万 | -7.19% |
| 08/17 | 267 | 267 | 258 | 262 | -2.24% | 120,500 | 30億8096万 | -6.09% |
| 08/16 | 273 | 276 | 266 | 268 | -5.63% | 177,700 | 31億5151万 | -4.29% |
| 08/15 | 279 | 287 | 278 | 284 | +1.07% | 45,200 | 33億3966万 | +1.43% |
| 08/14 | 15:05 営業外収益及び特別損失の計上に関するお知らせ |
| 08/14 | 15:05 2024年3月期第1四半期決算短信〔日本基準〕(非連結) |
| 08/14 | 282 | 285 | 281 | 281 | -0.71% | 13,700 | 33億439万 | +0.36% |
| 08/10 | 277 | 285 | 277 | 283 | +1.07% | 44,500 | 33億2791万 | +1.07% |
| 08/09 | 282 | 282 | 277 | 280 | 0% | 20,200 | 32億9263万 | 0% |
| 08/08 | 280 | 286 | 280 | 280 | -0.36% | 25,700 | 32億9263万 | -0.36% |
| 08/07 | 278 | 283 | 277 | 281 | +0.72% | 32,500 | 33億439万 | 0% |
| 08/04 | 278 | 280 | 278 | 279 | +0.36% | 7,800 | 32億8087万 | -0.71% |
| 08/03 | 280 | 282 | 276 | 278 | -1.42% | 30,700 | 32億6911万 | -1.07% |
| 08/02 | 278 | 285 | 278 | 282 | +0.36% | 30,200 | 33億1615万 | +0.36% |
| 08/01 | 277 | 283 | 277 | 281 | +0.72% | 50,500 | 33億439万 | 0% |
| 07/31 | 276 | 283 | 276 | 279 | +1.45% | 68,700 | 32億8087万 | -0.71% |
| 07/28 | 278 | 278 | 274 | 275 | -1.79% | 46,700 | 32億3383万 | -2.48% |
| 07/27 | 279 | 281 | 278 | 280 | 0% | 16,700 | 32億9263万 | -0.71% |
| 07/26 | 280 | 280 | 277 | 280 | -0.36% | 22,300 | 32億9263万 | -1.06% |
| 07/25 | 283 | 283 | 278 | 281 | -0.71% | 25,800 | 33億439万 | -0.71% |
| 07/24 | 13:00 The 13th JSH International Symposium 2023においてPPMX-T003臨床試験中間報告が行われました |
| 07/24 | 282 | 295 | 281 | 283 | +0.71% | 123,100 | 33億2791万 | -0.35% |
| 07/21 | 280 | 284 | 279 | 281 | +0.72% | 23,800 | 33億439万 | -1.06% |
| 07/20 | 278 | 282 | 278 | 279 | -0.36% | 20,700 | 32億8087万 | -1.76% |
| 07/19 | 280 | 281 | 278 | 280 | +0.36% | 13,800 | 32億9263万 | -1.75% |
| 07/18 | 284 | 284 | 279 | 279 | -0.71% | 11,000 | 32億8087万 | -2.11% |
